Compass Therapeutics (CMPX) Accumulated Expenses (2019 - 2026)

Compass Therapeutics (CMPX) has 8 years of Accumulated Expenses data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 20.58% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 20.58% YoY), and the FY2025 full-year result was $11.4 million, up 81.06% from the prior year.
• Accumulated Expenses declined to $1.2 million in Q1 2026, from $11.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.4 million in Q4 2025 to a low of $490000.0 in Q1 2022.
• A 5-year average of $3.6 million and a median of $2.3 million in 2024 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 618.65% in 2022, while the deepest fall reached 82.27% in 2022.
• Tracing CMPX's Accumulated Expenses over 5 years: stood at $1.6 million in 2022, then grew by 24.55% to $1.9 million in 2023, then jumped by 224.41% to $6.3 million in 2024, then soared by 81.06% to $11.4 million in 2025, then plunged by 89.59% to $1.2 million in 2026.
• Business Quant data shows CMPX's Accumulated Expenses at $1.2 million in Q1 2026, $11.4 million in Q4 2025, and $2.5 million in Q3 2025.